300 North Capital’s Neurocrine Biosciences NBIX Stock Holding History

300 North Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-56,031	Closed	-$2.23M	–	73
2015 Q1	$2.23M	Sell	56,031 -2,429	-4%	-$86.9K	0.49%	79
2014 Q4	$1.31M	Buy	+58,460	New	+$1.11M	0.3%	86
2014 Q2	–	Sell	-51,189	Closed	-$824K	–	112
2014 Q1	$824K	Buy	51,189 +2,669	+6%	+$45.7K	0.21%	84
2013 Q4	$454K	Sell	48,520 -3,700	-7%	-$36.1K	0.13%	82
2013 Q3	$591K	Buy	+52,220	New	+$718K	0.14%	103

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

300 North Capital's NBIX Position: Q2 2015 in Review

300 North Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2015, closing a stake of 56,031 shares — an estimated $2.23M sold.

300 North Capital first reported a position in NBIX in Q3 2013 and held it in 5 quarters. The position peaked at $2.23M in Q1 2015. 199 funds tracked by Wall St. Rank hold NBIX as of Q2 2015.

300 North Capital reported no remaining Neurocrine Biosciences position as of Q2 2015 after selling out during the quarter.
300 North Capital sold 56,031 Neurocrine Biosciences shares in Q2 2015, an estimated $2.23M.
300 North Capital first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 5 quarters.
300 North Capital's Neurocrine Biosciences position peaked at $2.23M in Q1 2015.
199 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.